ArticleNeuroscience2015
Recombinant T-cell receptor ligand RTL1000 limits inflammation and decreases infarct size after experimental ischemic stroke in middle-aged mice.
Article in Neuroscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- The immunology of stroke and dementia.Immunity · 2025Review
- Targeting brain-peripheral immune responses for secondary brain injury after ischemic and hemorrhagic stroke.Journal of neuroinflammation · 2024Review
- Bystanders or not? Microglia and lymphocytes in aging and stroke.Neural regeneration research · 2023Review
- Identification of cell death-related biomarkers and immune infiltration in ischemic stroke between male and female patients.Frontiers in immunology · 2023Article
- The immune response of T cells and therapeutic targets related to regulating the levels of T helper cells after ischaemic stroke.Journal of neuroinflammation · 2021Review
- Comprehensive Landscape of Immune Infiltration and Aberrant Pathway Activation in Ischemic Stroke.Frontiers in immunology · 2021Article
- The "Dialogue" Between Central and Peripheral Immunity After Ischemic Stroke: Focus on Spleen.Frontiers in immunology · 2021Review
- Sex differences in the therapeutic effects of anti-PDL2 neutralizing antibody on stroke.Metabolic brain disease · 2019Article
- Review
- Article
- Differential gene expression profiles between two subtypes of ischemic stroke with blood stasis syndromes.Oncotarget · 2017Article
- Upregulation of CD74 and its potential association with disease severity in subjects with ischemic stroke.Neurochemistry international · 2017Article
- Partial MHC class II constructs as novel immunomodulatory therapy for stroke.Neurochemistry international · 2017Review
- Partial MHC Constructs Treat Thromboembolic Ischemic Stroke Characterized by Early Immune Expansion.Translational stroke research · 2016Article
- Insulin-Like Growth Factor (IGF)-I Modulates Endothelial Blood-Brain Barrier Function in Ischemic Middle-Aged Female Rats.Endocrinology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
We have previously demonstrated that recombinant T-cell receptor ligand 1000 (RTL1000) reduces infarct size and improves long-term functional recovery after experimental stroke in young transgenic mice expressing human leukocyte antigen DR2 (DR2-Tg). In this study, we determined the effect of RTL1000 on infarct size in 12-month-old middle-aged DR2-Tg mice, and investigated its mechanism of action. Twelve-month-old male DR2-Tg mice underwent 60min of intraluminal reversible middle cerebral artery occlusion (MCAO). Vehicle or RTL1000 was injected 4, 24, 48 and 72h after MCAO. Cortical, striatal and total hemispheric infarcts were measured 96h after stroke. Spleen and brain tissues were collected 96h after stroke for immunological analysis. Our data showed that RTL1000 significantly reduced infarct size 96h after MCAO in middle-aged male DR2-Tg mice. RTL1000 decreased the number of activated monocytes/microglia cells (CD11b(+)CD45(hi)) and CD3(+) T cells in the ischemic hemisphere. RTL1000 also reduced the percentage of total T cells and inflammatory neutrophils in the spleen. These findings suggest that RTL1000 protects against ischemic stroke in middle-aged male mice by limiting post-ischemic inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.